

***Connecting and advancing health
sciences in partnership with
academic and clinical institutions***

**from Open access to Artificial Intelligence Discovery
tools - Karger Publishers offers services that make
the world of research go round**



BMF - Helsinki, November 2019

Overview

1. Introduction
2. The Karger Approach
3. Qinsight – AI Discovery tool
4. Karger - Open for Open
5. Q & A



1. Introduction

A Family Business

- Founded by Samuel Karger in 1890
- Managed by the 4th generation of the Karger family
- Headquarters at Basel (Switzerland)
- International organization:
Regional offices on 5 continents
and collaboration with
representatives in the whole world



1. Introduction

Facts and Figures

- 104 journal titles (28 Open Access)
- Fast Facts medical handbooks : 33 new books in 2019
- 15 new book titles per year
- Publication language: English (97%)
- 8'100 published articles
- 170 Editors-in-Chief & 3'250 Editorial Board Members worldwide
- approx. 12'800 Peer Reviewers worldwide
- Development of new tools, services and apps

1. Introduction

A long history...


Many Karger titles have a long history, published for many decades – well-established journals of high reputation that in their area serve as a forum for the latest developments and findings of basic and clinical research:

Dermatology (1893)

Psychopathology (1897)

Cardiology (1937)

Advances in Cardiology (1939)



2019 – a new strategy


- A new mission statement: Connecting and advancing health sciences
Knowledge that matters. Experiences that make a difference.
- Karger established 2 main divisions :
 - “Academic and Research Markets” (ARM) – with services for academic institutions, societies and research companies.
 - “Karger Clinical & Healthcare Clients” - providing scientific findings edited for clinicians and patients.
- Libraries and publishers have always shared a core mission
→ to help knowledge reach the people who need it.
- Open Access is re-defining the roles of libraries/institutions and publishers.
- Therefore, our focus is shifting to filtering, generating and publishing content – content that matters.
- This means that the entire cycle of knowledge is coming into the picture...

2. The Karger Approach.

The Cycle of Knowledge

Our mission is to connect and advance health sciences.

We have developed new services and partnerships, that cover diverse needs along the research cycle:



Publish

In partnership with institutes, our solutions make it easy for faculty members to publish Open Access with a reputed publisher.

- Publish & Access with APC vouchers, combining access to the complete Karger collection and publishing options in all Karger journals
- Start your own Open Access Partner Publication with Karger: now offering a step by step program for institutions and societies.

Access

Complete collection, customized collection, subject package, individual journal subscription or topic article package: let us provide you with an access model that fits your needs!




Curate

Searching through a flood of content, trying to find and compile the relevant information can be extremely time consuming. We are proud to support you and your faculty in the task of curation and simplify the research process with the AI-based discovery solution **Q^{insight}!**




Services

In cooperation with Enago, as of fall 2019 Karger will offer a wide range of educational workshops and trainings for a broad variety of audiences, from young authors just starting their careers to reviewers and editors. All workshops can be held online or in person, depending on your preferred method and setting. Additional services covering more needs will follow in the future.



Dermakonsil –
an app for
dermatologists

Fast Facts Medical handbooks for clinicians & for patients



Karger

All Courses

Ask Our Experts

Author Services

FAQs

Sign In

Powered by
enago
Author First. Quality First

Struggling with writing and publishing your research?

We can guide you through the publication process and help you achieve success.

Register Now

Karger LEARN
platform and
educational
services



15+ Courses

Covers all aspects of academic publishing



Discuss your problems

Get solutions to your publication
problems from experts



Learn from experts

Avg. experience of our experts is more
than 20 years

3. Qinsight: Searching Biomedical Literature with AI

3. Qinsight – discover, explore, analyse

What is Qinsight ?

- An AI-based platform, enabling efficient discovery of relevant results
- It is specialized in Biomedical literature
- Qinsight allows you to search in natural language
- Qinsight finds meaningful relationships between concepts and predictions not possible with other systems
- Covering >40 million documents, including >10M full-text



Access to which Content ?

- Journal articles – All biomedical articles including all of PubMed/MEDLINE, plus full-text non-open access articles from publisher partners (ex: Karger, OUP)
- Clinical Trials – covering all content from clinicaltrials.gov
- NIH Grants – providing insight into what is being worked on even before journal publication
- Patent Grants – covering full-text for all granted US patents
- Patent Applications – covering full-text for all US patent applications
- AHRQ Treatment Guidelines – covering clinical practice guidelines from the National Guidelines Clearinghouse
- Toxline – including both NTIS documents and Riskline
- HSTalks – online seminars by leading world experts, covering biomedicine and life sciences
- Health and Life Science News – providing access to breaking information without waiting for full publication. If you have a subscription to Factiva from Dow Jones, that deep news source can also be integrated into your *Qinsight* subscription.

Q CXCL8 and glioma

SEARCH

Use **Power Term**[®] classes and proper capitalization for best results

Authors/Inventors

Journals

Affiliations/Assignees/Sponsors

Help

Clear All

Open Guide

Show Additional Patent Search Options +

Applied Filters

None

Filters

Published Within

Last 30 days

Last year

Last 3 years

Last 5 years

Custom Range

Publication Type

Journal Articles »

Clinical Trials »

Patents »

AHRQ Guideline

NIH Grant

News »

More »

Focused Results (437)

Broader Results (3,433)

★ Save Search+Filters

Export ☒ ☐ ☐ Selected: 0

Show All Relevant Statements

Turn Highlighting Off

Sort by Date

- ☐ **Regulation of *IL-8* gene expression in gliomas by microRNA miR-93.** My Library
Fabbri E (Department of Life Sciences and Biotechnology Section of Biochemistry and Molecular Biology University of Ferrara Via Fossato di Mortara)
More Authors »
BMC Cancer (2015) Show Abstract »
IL-8 is a putative target of miR-93 in gliomas
More Relevant Statements »
- ☐ **Necrotic cells influence migration and invasion of glioblastoma via NF-κB/AP-1-mediated *IL-8* regulation.** My Library
Ahn SH (Tissue Injury Defense Research Center School of Medicine Ewha Womans University Seoul Korea.)
More Authors »
Sci Rep (2016) Show Abstract »
IL-8 promotes tumoral angiogenesis and increases brain endothelial cell permeability in glioblastoma.
More Relevant Statements »
- ☐ **Critical Role of *IL-8* Targeting in Gliomas.** My Library
Kosmopoulos M (Department of Biological Chemistry Medical School National and Kapodistrian University of Athens 11527 Athens. Greece.)
More Authors »

Also Containing

☐ In the Relevant Statements
 ☐ Anywhere

Not Containing

☐ In the Relevant Statements
 ☐ Anywhere

Negative Statements

[Exclude Negatives](#)
[Show Only Negatives](#)

Category

Key Concepts

glioma

glioblastoma

astrocytoma

ependymoma

oligodendroglioma

pilocytic astrocytoma

diffuse intrinsic pontin...

General Concepts

cell

expression

cancer

IL6

human

angiogenesis

VEGFA

level

increase

cell culture

More »

Actions

expression

induction

[Curr Med Chem](#) (2017) [Show Abstract »](#)

Interleukin-8 (*IL-8*) has been revealed as a critical regulator of *CNS* function and development with participation in many *CNS* disorders including gliomas.

[More Relevant Statements »](#)

4 ☐ [Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.](#)

Hasan T (Department of Neurological Surgery Feinberg School of Medicine Northwestern University Chicago IL USA.)

[More Authors »](#)

[Cell Death Dis](#) (2019) [Show Abstract »](#)

In sum, our data show that *IL-8* is a key microenvironmental factor involved in promoting cellular plasticity in *GBM*.

[More Relevant Statements »](#)

5 ☐ [The Process and Regulatory Components of Inflammation in Brain Oncogenesis.](#)

Mostofa AG (Department of Biomedical Sciences and Cancer Biology Center School of Pharmacy Texas Tech University Health Sciences Center)

[More Authors »](#)

[Biomolecules](#) (2017) [Show Abstract »](#)

High-grade gliomas show increased expression of *IL-8*.

[More Relevant Statements »](#)

6 ☐ [Cytokine patterns in brain tumour progression.](#)

Albulescu R (Victor Babes National Institute of Pathology 99-101 Splaiul Independentei 050096 Bucharest Romania.)

[More Authors »](#)

[Mediators Inflamm](#) (2013) [Show Abstract »](#)

Many studies showed that *IL8* is upregulated in gliomas and is involved in the promotion of angiogenesis.

[More Relevant Statements »](#)

7 ☐ [Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.](#)

Chulpanova DS (OpenLab Gene and Cell Technologies Institute of Fundamental Medicine and Biology Kazan Federal University Kazan Russia.)

[More Authors »](#)

[Front Pharmacol](#) (2018) [Show Abstract »](#)

IL-8 dependent recruitment of *MSCs* was also detected in glioma.

[More Relevant Statements »](#)

8 ☐ [The prolyl isomerase Pin1 regulates the *NF-kappaB* signaling pathway and interleukin-8 expression in glioblastoma.](#)

Atkinson GP (Department of Cell Biology University of Alabama at Birmingham Birmingham AL 35294-0006 USA.)

[More Authors »](#)

[Oncogene](#) (2018) [Show Abstract »](#)

IL-8 is particularly important in tumor angiogenesis, and studied extensively with respect to human gliomas.

[More Relevant Statements »](#)

9 ☐ [IL-8 is a mediator of NF-kB induced invasion by gliomas.](#)


Ravchaudhuri B (Brain Tumor and Neuro-Oncology Center Neurological Institute Cleveland Clinic 9500 Euclid Avenue ND40 Cleveland OH 44195)

Predictive Visual Analytics

Concept Trends : CXCL8 and glioma

 Export Data
 Save Image
 Reset

A red border indicates a growing trend; a blue border indicates a waning trend; and a gray border indicates no significant momentum change.




- Visual analytics help us to understand and explore information.
- The **Concept Cloud** visualizes the answers to questions like:
- How do concepts relate to each other?
- Are there any emerging trends?
- What other concepts should I pay attention to?

The **red** fringe indicates a growing trend in research, a **blue** fringe indicates a waning trend, grey no significant momentum change

Visual Analytics

Not just their simple co-occurrence in a document, but visualizing the strength and significance of the connections.

Find and highlight the most relevant results – with Qinsight.



5 Reasons why...

... Qinsight would help you:

1. Qinsight enables efficient discovery of relevant results.
2. Qinsight saves time by producing relevant results quickly, instead of overwhelming lists.
3. Qinsight finds meaningful relationships between concepts and predictions not possible with other systems.
4. Qinsight helps in many different contexts: early phase research (ex: predictive analysis), as a valuable complement to traditional Systematic Review approach, etc.
5. Qinsight is easy to use!

Qinsight – our proposal

- Invite you to look at a recorded webinar (28mn) made by Jeff Saffer, one of the founder of Qinsight, explaining and showing how Qinsight works.
 - The topic chosen to illustrate this is “metformin and diseases”.
 - We offer academic and hospital institutions a free trial of a month.
 - During the trial you would receive documentation and Tips on how to best use Qinsight, it can also start with a training session by one of the team members.
- > Have a look at <https://www.quetzal-search.info> for more information

4. Karger: Open for Open



4. The Karger Approach.

Open Access – Open Science

The Future is Open. The Future is now.

Karger understands Open Access as one part of the Open Science movement, which we see as essential, exciting developments.

We are moving towards an open access-based publishing landscape in the academic world.

However, not all (geographical) markets are moving and evolving at the same speed, OA is driven by different stakeholders with different requirements. As a publisher we need to try and accomodate these to the best we can.

→ The aim today is to give you a short overview on our approach to Open Access and open the discussion.

4. Karger: Open for Open

How Karger is helping advance the OA transition

- Green OA policy (generous policy – technical support e.g. Deep Green, NIH transfers)
- Improving workflows, reporting capabilities (responding to stakeholder needs)
- Policies to support OA, researcher needs/funder requests, e.g. supporting sharing of preprints
- Flexible transitioning models based on market/institution requirements
- The strategy emphasizes partnership with institutions, societies, researchers. → Understanding your needs !

4. Karger: Open for Open

Open Access: Flipping of Journals

In 2020 we have started actively flipping of journals from subscription model to OA:


Gastrointestinal Tumors

Inflammatory Intestinal Diseases

Kidney Diseases

Lifestyle Genomics

Liver Cancer




4. Karger: Open for Open

Publishing Services & Agreements, main models

1. «Partner Publications»:

A journal is published in cooperation with an institution. Ideally fully financed by the partnering institution (no APCs for authors)
= Platinum Open Access

→ Model in the Middle East



4. Karger: Open for Open

Publishing Services & Agreements, main models

2. Vouchers for OA Publishing:

Upfront payment for publishing Open Access articles in Open Access or hybrid journals, in combination with Access to the Karger collections.

→ mostly in emerging markets: Russia, Latin America, India

3. Offsetting Deal:

Also called Transformative agreements.

→ Part of the existing sales revenue is used for publishing services (APCs)

4. Karger: Open for Open

Karger Offsetting Agreements

- Active Deal since 2016, with the UKB in the Netherlands, currently running in the second term
- For 2020 in discussions with various European Consortia: Sweden, Germany, Czech Elib, JISC (UK), ...
- Pilot Projects in the US market
- Different Models based on market and consortia requirements: *including Publish-and-Read, Read-and-Publish, Voucher-based, credit deposit based*
- Karger guarantees budget security and cost caps (first and second/third year)

4. Karger: Open for Open

Working together towards Open Access and Open Science

Karger's new strategy sails under the slogan «Connecting and Advancing Health Sciences».

We continue to work on improving our workflows and making transformative agreements.

We are striving for our customers to become more than our customers – striving for them to become **our partners**.

By understanding your needs and adapting to the new environment, we aim to continue contributing to progress in medical research.

So... tell us what you need !

For any question, documentation,
or set-up of a trial, don't hesitate

We are there to listen to you !
😊

Karger contact:

Séverine Maes
Regional Manager Northern Europe
s.maes@karger.com

